Melanoma: How Skin Cancer Can Spread Beyond the Skin
When 46-year-old Leland Fay noticed a small black mole on his head, he didn’t think much of it. A dermatologist froze it off during a routine exam in 2012. But when the mole returned—bigger than before—biopsy revealed devastating news: melanoma that had already spread to distant sites. When the Monument, Colorado native was diagnosed with melanoma, he was given a bleak prognosis due to the advanced stage of the tumor — it had already reached stage IV. Leland hadn’t thought much of the little black mole on his head a few months earlier. After a biopsy and imaging tests, doctors told Leland it was melanoma, and that it had already spread Skin Cancer Foundation. His case illustrates melanoma’s most dangerous characteristic: its ability to metastasize beyond the skin to vital organs.
The Journey From Skin To Lymph Nodes
Unlike most skin cancers that rarely spread, melanoma has extraordinary metastatic potential. In melanoma patient’s metastasis to regional lymph nodes via lymphatics is the most common form of spread, with around 50% of those who develop metastases having nodal disease as their first site of clinically-detected recurrence. However, metastasis in a distant organ with no evidence of previous or current lymph node disease is seen in about 30% of those who develop metastatic melanoma suggesting dissemination of malignant cells exclusively via the bloodstream PubMed Central.
The lymphatic system—a network transporting immune cells and waste throughout the body—becomes melanoma’s highway for spread. Normally, the first place a melanoma tumor metastasizes to is the lymph nodes, by literally draining melanoma cells into the lymphatic fluid, which carries the melanoma cells through the lymphatic channels to the nearest lymph node basin. Unfortunately, when melanoma cells are carried to the lymph nodes, they can potentially be carried beyond the nodes to distant organs Skin Cancer Foundation.
Lymph node metastases are often diagnosed earlier than metastases at distant sites, with a median interval of 16 months between primary diagnosis and the detection of nodal metastasis in one study, while distant metastases tend to be detected a median of 25–40 months after primary diagnosis. This pattern suggests that bloodstream spread likely occurs later than lymphatic spread PubMed Central. Stage 3 melanoma—cancer that has reached lymph nodes—represents a critical turning point. Approximately 5 percent of people are diagnosed with melanomas that have spread to distant parts of the body. The percentage of people diagnosed with melanoma that has spread to nearby lymph nodes is 10 percent City of Hope.
Where Melanoma Spreads
Once melanoma enters the bloodstream, it can colonize virtually any organ. Metastatic melanoma typically occurs in sites such as lymph nodes, skin, lungs, liver, brain, and bones. This metastatic spread often indicates advanced disease, with significantly decreased treatment efficacy and patient survival rates Nature.
The most common distant metastasis sites include lungs, liver, brain, and bones. Brain metastases prove particularly deadly. The initial location of metastases in our patients was as it follows brain – 43.5%, extra-regional lymph nodes and subcutaneous tissue – 27.4%, lung – 14.5%, digestive tract – 12.9%. The median overall survival, estimated for the group of patients who developed metastases, was of only 5.3 months. The 1 year OS of patients with brain dissemination was of 0% in our study PubMed Central.
Some patients develop unusual metastatic sites—ovaries, breast tissue, gastrointestinal tract. About one-third of stage 4 patients have simultaneous invasion of multiple organs at diagnosis, compounding treatment challenges.
The Timing Question: When Does Spread Occur?
Research reveals a troubling reality: melanoma often metastasizes long before diagnosis. Available evidence suggests that melanoma metastasis has often occurred many months before a primary melanoma diagnosis is made. In a study based on observations of the size of sentinel lymph node metastases, backwards extrapolation indicated that the first metastatic cell reached the sentinel lymph node approximately 18 months before the primary melanoma was diagnosed PubMed Central.
This early dissemination explains why even thin melanomas—those under 1mm thick—sometimes metastasize. Up to 15% of thin melanomas eventually spread despite appearing low-risk initially. The implication: by the time you notice a changing mole, microscopic spread may have already occurred in aggressive cases.
Survival: The Stark Reality Of Stage
On average, the estimated five-year survival rate for melanomas detected while still localized is very high: about 99 percent in the U.S. The chances of curing a melanoma drop sharply once it spreads, or metastasizes, beyond the original tumor site. Once a melanoma has metastasized beyond the original tumor site to the lymph nodes, it is considered a stage III melanoma. The five-year survival rate then drops to around 74 percent. Once a tumor has spread to distant body sites such as organs, it is considered a stage IV melanoma, with an estimated five-year survival rate of only 35 percent Skin Cancer Foundation.
For Stage 3 melanoma, the melanoma-specific survival rate ranges from 93% to 32% 5 years after the initial melanoma diagnosis MRA. The wide range reflects subdivisions within stage 3—those with microscopic nodal involvement fare far better than those with bulky lymph node masses or in-transit metastases.
However, recent advances offer hope. According to the American Cancer Society, the 5-year survival rate for stage 4 melanoma is 35%. The Memorial Sloan Kettering Cancer Center suggests that the survival rate has increased to 50% due to newer treatment options. Newer treatment options can control advanced melanoma for years and even cure it Medical News Today.
Treatment Revolution: Immunotherapy And Beyond
Treatment options for stage 4 melanoma have expanded greatly in the last 10 years. For patients who have a limited number of metastases, surgery could be possible, or stereotactic radiation therapy. For metastases that are more widely spread, systemic therapies including immunotherapies and targeted therapies (for melanomas with the BRAFV600 tumor biomarker) as well as a new cell-based therapy can be used MRA.
Checkpoint inhibitors—drugs releasing immune system brakes—have revolutionized melanoma treatment. Pembrolizumab, nivolumab, and ipilimumab activate T-cells to attack melanoma throughout the body. For melanomas harboring BRAF mutations (about 50% of cases), targeted therapy combinations attack specific genetic vulnerabilities.
For Stage 4 melanoma, depending on the treatment, overall survival rates at 5 years of 52% and 34% have been reported MRA. Some patients achieve complete responses—no detectable cancer—maintained for years. While not universal, these outcomes represent dramatic improvements over historical survival measured in months.
Leland Fay benefited from this revolution. Through surgeries, immunotherapy, radiation, and unwavering support, he beat the odds. Five years after diagnosis, he leads an active life, though acknowledging: “Better to have a little inconvenience with a biopsy than let melanoma advance.”
References
- PMC. When does a melanoma metastasize? https://pmc.ncbi.nlm.nih.gov/articles/PMC11174830/
- Cancer Center. Metastatic Melanoma Stage 3 and 4 Symptoms, Survival Rate. https://www.cancercenter.com/cancer-types/melanoma/types/metastatic-melanoma
- PMC. Survival rates of patients with metastatic malignant melanoma. https://pmc.ncbi.nlm.nih.gov/articles/PMC4316142/
- Skin Cancer Foundation. How Dangerous is Melanoma? It’s All a Matter of Timing. https://www.skincancer.org/blog/dangerous-melanoma-matter-timing/
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
Follow Us on Twitter, Instagram, Facebook, & LinkedIn
